LONA · XBRL financial data

LeonaBio financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (LONA's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Research and development	27,202	23,680*	21,236	22,154	17,922	9,370*	4,302	3,661	2,825	6,712*	11,262	12,702
General and administrative	7,840	6,962*	6,451	5,874	7,572	6,196*	5,234	3,630	4,049	3,765*	6,881	6,576
Operating income (loss)	(35,042)	(29,014)*	(27,687)	(28,028)	(29,621)	(15,566)*	(9,536)	(7,291)	(6,874)	(78,565)*	(17,214)	(19,453)
Other income (expense)	2,072	1,729*	1,350	1,169	880	563*	393	325	263	255*	586	446
Income tax expense (benefit)	—	—	—	—	—	—	—	—	—	year only	—	—
Net income (loss)	(32,970)	(27,285)*	(26,337)	(26,859)	(28,741)	(15,003)*	(9,143)	(6,966)	(6,611)	(82,889)*	(32,948)	(19,007)
Earnings per share, basic‡ USD per share	(8.70)	(7.20)*	(6.90)	(7.00)	(7.50)	(3.90)*	(2.30)	(1.80)	(1.68)	—	(1.73)	(0.80)
Earnings per share, diluted‡ USD per share	(8.70)	(7.20)*	(6.90)	(7.00)	(7.50)	(3.90)*	(2.30)	(1.80)	(1.68)	—	(1.73)	(0.80)
Weighted average shares, basic‡ thousands of shares	3,805	3,810*	3,832	3,838	3,852	3,870*	3,904	3,909	3,944	5,334*	19,027	23,726
Weighted average shares, diluted‡ thousands of shares	3,805	3,810*	3,832	3,838	3,852	3,870*	3,904	3,909	3,944	5,334*	19,027	23,726

‡ Per-share figures and share counts are adjusted for the 1-for-10 stock split (December 2025); filings made before it reported them unadjusted.

Balance sheet

CSV

Fiscal quarters (LONA's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	110,334	90,584	77,821	73,828	68,856	48,438	26,422	19,888	20,874	69,276	32,833	32,323
Short-term investments	62,614	56,835	44,267	17,941	—	2,837	10,248	9,935	4,352	19,055	34,846	18,744
Prepaid and other current assets	5,556	5,682	4,920	4,934	3,145	3,566	3,183	2,395	1,799	1,127	1,523	3,741
Total current assets	178,504	154,729	128,636	106,704	82,002	54,841	39,853	32,218	27,025	89,458	69,202	54,808
Property and equipment, net	3,633	3,388	3,144	2,930	2,687	2,444	2,201	1,958	1,715	1,472	1,241	1,014
Right-of-use asset	1,105	1,049	992	933	871	808	743	676	607	535	461	386
Total assets	184,700	160,245	133,458	111,253	86,246	58,779	43,513	35,545	30,033	92,151	71,590	56,894
Accounts payable	1,711	129	681	475	388	319	867	171	266	4,587	1,764	2,420
Accrued liabilities	16,553	18,343	14,537	16,036	16,961	12,402	4,199	2,371	2,069	4,963	4,424	4,906
Total current liabilities	28,622	28,840	25,598	26,902	27,751	13,135	5,492	2,981	2,787	47,503	6,666	7,817
Lease liability, non-current	1,314	1,217	1,118	1,016	912	803	691	578	460	338	213	86
Total liabilities	29,936	30,057	26,716	27,918	28,663	13,938	6,183	3,559	3,247	64,361	22,287	23,299
Accumulated deficit	(281,921)	(309,206)	(335,543)	(362,402)	(391,143)	(406,146)	(415,289)	(422,255)	(428,866)	(511,755)	(544,703)	(563,710)
Total stockholders' equity	154,764	130,188	106,742	83,335	57,583	44,841	37,330	31,986	26,786	27,790	49,303	33,595
Total liabilities and equity	184,700	160,245	133,458	111,253	86,246	58,779	43,513	35,545	30,033	92,151	71,590	56,894
Common shares outstanding (cover page)‡ thousands of shares	3,805	3,833	3,833	3,844	3,867	3,904	3,904	3,944	3,944	9,336	9,394	9,422

‡ Per-share figures and share counts are adjusted for the 1-for-10 stock split (December 2025); filings made before it reported them unadjusted.

Cash flows

CSV

Fiscal quarters (LONA's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(32,970)	(27,285)*	(26,337)	(26,859)	(28,741)	(15,003)*	(9,143)	(6,966)	(6,611)	(82,889)*	(32,948)	(19,007)
Stock-based compensation	2,494*	2,228*	2,679	3,205*	2,936*	2,229*	1,637	1,597*	1,410*	1,458*	662	3,181*
Net cash from operating activities	(23,984)*	(26,293)*	(25,804)	(22,330)*	(23,023)*	(26,013)*	(14,665)	(6,999)*	(4,668)*	(19,397)*	(20,903)	(16,958)*
Purchases of property and equipment	30*	0*	5	28*	0*	0*	—	—	—	—	—	—
Net cash from investing activities	20,690*	6,391*	13,041	26,562*	18,039*	(2,812)*	(7,351)	441*	5,654*	(14,638)*	(15,540)	16,334*
Proceeds from issuing common stock	—	—	—	—	—	—	—	—	—	year only	—	—
Net cash from financing activities	0*	152*	—	—	12*	34*	—	—	0*	82,437*	—	—
Net change in cash	(3,294)*	(19,750)*	(12,763)	4,380*	(4,972)*	(28,791)*	(22,016)	(6,534)*	986*	48,402*	(36,443)	(510)*

Compare with peers

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
LeonaBio	32,323	not reported	(16,958)*	9.4M	3.0 quarters	Q2 FY26 10-QJun 30, 2026
Mannatech	6,034	26,650	(792)*	1.9M	7.6 quarters	Q2 FY26 10-QJun 30, 2026
Traws Pharma	5,016	not reported	(7,504)*	15.4M	0.7 quarters	Q2 FY26 10-QJun 30, 2026
BioCardia	4,117	not reported	(1,735)*	15.1M	2.4 quarters	Q2 FY26 10-QJun 30, 2026
Alaunos Therapeutics	124	0	(300)*	2.5M	0.4 quarters	Q2 FY26 10-QJun 30, 2026
Scienture Holdings	8,188	344	(3,132)*	41.1M	2.6 quarters	Q2 FY26 10-QJun 30, 2026
Raphael Pharmaceutical	1	not reported	0*	20.2M	—	Q2 FY26 10-QJun 30, 2026
Kiora Pharmaceuticals	7,077	not reported	(1,892)*	4.4M	8.9 quarters	Q2 FY26 10-QJun 30, 2026
Brainstorm Cell Therapeutics	22	not reported	(895)	11.0M	0.0 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.